nulojix 250mg powder for concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - belatacept - powder for solution for infusion - 250mg
benlysta 400mg powder for concentrate for solution for infusion vials
glaxosmithkline uk ltd - belimumab - powder for solution for infusion - 400mg
benlysta 120mg powder for concentrate for solution for infusion vials
glaxosmithkline uk ltd - belimumab - powder for solution for infusion - 120mg
desferal 500mg vials powder for solution for injection or powder for concentrate for solution for infusion
novartis ireland limited - deferoxamine mesilate - powder for solution for injection/infusion - 500 milligram(s) - iron chelating agents; deferoxamine
herceptin powder for concentrate for solution for infusion
bulk manufacturer - trastuzumab - powder for concentrate for solution for infusion - 440mg
alimta powder for concentrate for solution for infusion
lilly france (s.a.s). - pemetrexed (pemetrexed disodium heptahydrate) - powder for concentrate for solution for infusion - 500mg
vancomycin 1g powder for concentrate for solution for infusion vials
bowmed ibisqus ltd - vancomycin hydrochloride - powder for solution for infusion - 1gram
caspofungin fresenius kabi 50 mg powder for concentrate for solution for infusion
fresenius kabi deutschland gmbh - caspofungin - powder for concentrate for solution for infusion - 50 milligram(s) - other antimycotics for systemic use; caspofungin
caspofungin fresenius kabi 70 mg powder for concentrate for solution for infusion
fresenius kabi deutschland gmbh - caspofungin - powder for concentrate for solution for infusion - 70 milligram(s) - other antimycotics for systemic use; caspofungin
qarziba dinutuximab beta 4.5 mg/ml concentrate for solution for infusion, 20 mg/4.5 ml vial
recordati rare diseases australia pty ltd - dinutuximab beta, quantity: 4.5 mg/ml - solution - excipient ingredients: polysorbate 20; hydrochloric acid; sucrose; water for injections; histidine - qarziba is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response.